- Offering an overview of how our industry responded to the global pandemic
- Highlighting how our organization adapted our existing processes and programs to continue to work under extraordinary circumstances
- Discussing some of the key takeaways and lessons learned from the past year and a half
- Where do we go from here? How will AstraZeneca and the biopharmaceutical industry at large move forward from here? What are we doing today to pave the way to those objectives?
Pam Cheng joined AstraZeneca in 2015 as executive vice president of Global Operations and Information Technology (IT), guiding the company’s manufacturing, supply chain, procurement, and IT across 18 countries and leading a team of over 19,000. Under her leadership, AstraZeneca Global Operations has transformed significantly driving top performance across the business while delivering value back to the enterprise. The next phase of transformation includes the convergence of operational excellence and digital innovation, building the ‘Factory of the Future’.
Before AstraZeneca she spent 18 years in global manufacturing, supply chain, and commercial roles at Merck/MSD. As president of MSD China, she was responsible for MSD’s entire business in China—sales and marketing, commercial operations, and oversight of manufacturing and research and development. Prior to that, she was head of Global Supply Chain Management and Logistics for Merck and led the transformation of Merck supply chains across the global supply network. Before joining the Biopharmaceutical industry, she worked in engineering and project management roles at Universal Oil Products, Union Carbide Corporation, and GAF Chemicals.
In addition to her executive role at AstraZeneca, Pam is a nonexecutive director for the board at Smiths Group plc.
Ms. Cheng holds bachelor’s and master’s degrees in chemical engineering from Stevens Institute of Technology and an MBA in marketing from Pace University.